ReNeuron Group

ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal progenitor cells (hRPCs) are also being studied for RP (in Phase I/IIa).

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

Georgia Capital in 60 seconds

About Edison

About Edison

Careers

ReNeuron Group (AIM: RENE)

Latest Insights

ReNeuron Group — H124 results reaffirm focus on CustomEX

ReNeuron Group — A step forward on the Exosome delivery platform

ReNeuron Group — Full steam ahead with CustomEx

ReNeuron Group — Encouraging data for iPSCs opens potential

Sector

ReNeuron Group — Continuing to gain clinical data in eye disease

ReNeuron Group — Funding to complete Phase IIa and other projects

ReNeuron Group — Exploiting the potential of cell therapy

ReNeuron Group — Strong data in retinal therapy shows long effects

ReNeuron Group — Focus on retinal therapy, out-licensing of stroke

ReNeuron Group — Stable 12-month vision

ReNeuron Group — Zero overhang

ReNeuron Group — A transformational year

ReNeuron Group — FY19 prelims after a momentous second half

ReNeuron Group — Year-end update highlights transaction potential

ReNeuron Group — Early clinical data in RP continue to improve

ReNeuron Group — Long-awaited partnering floodgates open

ReNeuron Group — Exciting positive data in retinitis pigmentosa (RP)

ReNeuron Group — Formative event

ReNeuron Group — Open season on Exosome deals

ReNeuron Group — Time to reflect

ReNeuron Group — Exosomes rise further

ReNeuron Group — US exclusivity deal – more than non-dilutive cash

ReNeuron Group — The rise of the exosome

ReNeuron Group — Consolidation confusion?

ReNeuron Group — Biblical aspirations

ReNeuron Group — Milestones expected as pipeline progresses

ReNeuron Group — Clinical pipeline progressing as planned

ReNeuron Group — Global clinical pipeline strategy update

ReNeuron Group — Clinical pipeline progressing as planned

Executive Interview – ReNeuron

ReNeuron Group — Update 7 December 2016

ReNeuron Group — Update 5 August 2016

ReNeuron Group — Update 27 July 2016

Executive Interview – ReNeuron

ReNeuron — Update 24 March 2016

Executive Interview – ReNeuron